Bottom line
What is IVOCX's expense ratio?
IVOCX's expense ratio is 1.82%, or about $182 a year on every $10,000 invested. That is more expensive than 93% of mid-cap funds we track (median 0.88%). It has no front-end sales load. Its expense ratio includes a 1% 12b-1 marketing fee.
Updated Jul 29, 2026
IVOCX fee table
| Net expense ratio | 1.82% |
|---|---|
| Gross expense ratio | 2.04% |
| Management fee | 0.85% |
| 12b-1 (distribution) fee | 1% |
| Other expenses | 0.19% |
| Fee waiver / reimbursement | -0.22% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Jul 29, 2026
What IVOCX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| IVOCX | $285 | $618 | $1,078 | $2,351 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.82% expense ratio costs roughly $93,900 in lost growth, versus about $49,300 for the median mid-cap fund (0.88%).